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Background: The levonorgestrel intrauterine system, Mirena®, is widely used for contraception and the treatment
of idiopathic menorrhagia. Here, we reported one case of acute urticaria following Mirena® implantation to increase
the awareness of possible adverse side effects associated with Mirena®.
Case presentation: The case presented is a 27-year-old Chinese woman who received Mirena® implantation for her
adenomyosis and menorrhagia. The operation was successful and the patient did not experience any discomfort during
the operation. However, she developed acute urticaria on her entire body accompanied with pruritic, slight left lower
quadrant pain, and slight dizziness two hours after the operation. The patient was recommended to have the Mirena®
removed immediately, and she took 10 mg oral methylprednisolone and 5 mg desloratadine tablet daily for five
days. Her urticaria resolved and did not recur.
Conclusion: The patient’s acute urticaria seems to have been associated with the Mirena® levonorgestrel
intrauterine system implantation, since she had no history of allergic reactions to materials used during the
operation such as plastic, metal, alcohol, medications, and povidone-iodine.
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The levonorgestrel intrauterine system (LNG-IUS),
Mirena®, is a commonly used contraceptive device in
clinical practice. In addition to providing effective
contraception, Mirena® is also frequently used to treat
idiopathic menorrhagia and protect the uterus from
endometrial hyperplasia in estrogen replacement therapy
[1]. Adverse side effects associated with Mirena® im-
plantation include acne, menstrual disorder, pelvic pain,
and ovarian cysts. Most of these symptoms can resolve
spontaneously within several months [1-3]. Adverse skin
reactions to Mirena® are rare. Karri et al. reported one
case of severe seborrhoeic dermatitis, which is thought
to associate with the levonorgestrel in Mirena® [4]. Here,
we reported one case of acute urticaria following
Mirena® implantation. The patient was advised to have the* Correspondence: zhuhaiyandoc@sina.com
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prednisolone and 5 mg desloratadine tablet daily for five
days. Her urticaria then resolved and did not recur.
Case presentation
A 27-year-old Chinese woman gravida 1 para 1 was
treated with Mirena® implantation for adenomyosis and
menorrhagia in our hospital in September 2012. The pa-
tient was in good general health and had regular men-
strual cycles. She had a caesarean section to deliver a
baby boy in 2003. Six months after the delivery, she re-
ceived a triangular-shaped metal intrauterine device
(IUD) insertion for contraception. The IUD was then re-
moved two months later due to unbearable vaginal spot-
ting. The patient had a history of moderate alcohol
consumption but no history of allergic reactions to plas-
tic, metal, alcohol, medications, and povidone-iodine.
Her routine gynecological examination before the oper-
ation appeared normal.
A Mirena® LNG-IUS was inserted into her uterine cavity
according to the manufacturer’s instruction. The patienttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The operation was successful. However, 2 hours after the
operation, the patient developed an erythematous skin
rash on her body. The lesion first appeared around her
umbilical area, then on her chest, face, legs, arms,
and feet. The rash covered her entire body in a short
time (Figure 1A and B). Other symptoms accompanied
with the development of the rash included pruritic, slight
left lower quadrant pain, and slight dizziness. The patient
did not have fever, nausea, and vomiting. Her vital signs
appeared normal and stable. Her gynecological examin-
ation did not showed any significant abnormality. Her
vulva development was normal. She was sexually active
and had no prior vaginal delivery. Her genital skin and
mucosa did not exhibit any rash and congestion. Small
amount of bloody discharge was present in her vagina.
Her cervix was smooth. Her uterus was anteverted,
slightly enlarged, and soft. She did not feel tenderness
around uterus area. Her ovaries and ovarian attachments
did not show any obvious abnormality.
The diagnosis from a dermatologist was acute urticaria
possibly caused by allergic reactions. The patient was ad-
vised to have the Mirena® removed immediately. After
the Mirena® was removed, her pruritic was slightly re-
lieved. The patient then took 10 mg oral methylprednis-
olone and 5 mg desloratadine tablet daily for five days.
The patient came back to follow-up visit three days after
the operation. Her abdominal pain and pruritic resolved
completely, her skin condition also improved significantly
(Figure 1C and D). The medication was discontinued fiveFigure 1 Images of erythematous skin rash on the patients.
Eruption of erythematous skin rash on the patient’s chest (A) and
right forearm (B) two hours after the Mirena® implantation. The
urticaria on the patient’s chest (C) and right forearm (D) was
significantly relieved three days after the medication of oral
methylprednisolone and desloratadine tablet.days after the operation. Her urticaria subsided and did
not recur.
Discussion
The most commonly recognized side effects associated
with Mirena® are vaginal bleeding or spotting, amenor-
rhea, and benign ovarian cysts [1-3]. Although adverse
skin reactions to Mirena® are rarely seen, a few cases of
skin condition have been reported to associate with
Mirena® implantation. Karri et al. presented a case of
severe seborrhoeic dermatitis [4]. Levonorgestrel is the
hormonal component of the Mirena® LNG-IUS. The
patient’s seborrhoeic dermatitis is thought to be caused
by the levonorgestrel released from the Mirena®, because
her skin condition was improved quickly after the re-
moval of the Mirena®. Pereira et al. reported a case of
autoimmune progesterone dermatitis. In their report,
the patient developed itchy skin rash 24 hours after a
Mirena® IUS insertion. Her symptoms were initially alle-
viated by local steroid and oral antihistamines, but re-
solved eventually by the removal of the Mirena® IUS [5].
In this report, this was the first case of acute urticaria
possibly associated with Mirena® implantation we en-
countered in our hospital. This patient developed a rash
eruption on her entire body 2 hours after the implant-
ation. The lesions carry the typical characteristics of urti-
caria, such as intensive pruritus and becoming blanched
completely with pressure. To determine the possible as-
sociation between the lesions and the Mirena® implant-
ation, we carefully examined the patient’s condition and
medical history. The patient had no food intake before,
during, and after the operation, eliminating food related
allergic reactions. She was not on any regular medication
and had no new medicines before the operation. Thus,
drug allergies might be excluded. In addition, she had no
history of allergic reactions to any medication or the ma-
terial used during the operation including plastic, metal,
alcohol, and povidone-iodine. The patient had no recent
or chronic infections or other medical conditions. The
only medical procedure she was exposed to was the Mir-
ena® implantation. Based on these facts, we concluded
that her urticarial condition was most likely due to the
Mirena® implantation. Similar to the reports from Karri
et al. and Pereira et al., the acute urticaria in this case
might also be associated with the levonorgestrel released
from the Mirena® LNG-IUS.
Although the rash is likely associated with Mirena® im-
plantation, limitations regarding the diagnosis should not
be ignored. Our diagnosis of Mirena® -induced acute urti-
caria is mainly based on the fact that the rash appeared
2 hours after the implantation and the patient did not have
previous allergic reactions to the materials used during the
operation. However, since we did not examine the serum
levels of immunoglobulins indicating possible allergic
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as plastic, metal, alcohol, and povidone-iodine, the possibil-
ity that these things might contribute to the development
of acute urticaria in this patient cannot be excluded com-
pletely. In addition, it has been known that emotional
stress can induce acute urticaria as well. According to the
patient’s medical history, in 2003, she had caesarean sec-
tion and triangular-shaped metal IUD insertion for contra-
ception, which have a similar operating procedure as
Mirena® LNG-IUS implantation. Although the patient was
not recorded to exhibit any abnormal reactions to the two
previous operations, she might experience unusual anxiety
and fear during the Mirena® implantation. Thus, we cannot
completely rule out the possibility that the acute urticaria
in this case might relate to the operation procedure but
not directly associate with the Mirena® LNG-IUS device.
The levonorgestrel released from Mirena® is at a higher
concentration in the uterus than that in the systemic cir-
culation. Thus, the side effects of Mirena® are usually local
and mild. We reported this case of acute urticaria possibly
associated with Mirena® implantation to raise the aware-
ness of the side effects of Mirena® and emphasize the
prompt treatment for the adverse reactions.
Conclusion
We reported one case of acute urticaria possibly associ-
ated with Mirena® implantation. The patient’s adverse
skin reaction might relate to the levonorgestrel released
from the Mirena® LNG-IUS. Her symptoms were im-
proved by oral steroid and antihistamines and removal
of the Mirena®, and did not recur after the medication
was discontinued.
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